Hypermobility Workup
Begin with the Beighton score to assess for generalized joint hypermobility (GJH), then systematically evaluate for connective tissue features and exclude alternative diagnoses through targeted genetic testing. 1
Initial Clinical Assessment: The Beighton Score
The Beighton scoring system is your primary screening tool and should be incorporated into routine practice 1:
Scoring thresholds for positive GJH:
- ≥6/9 points in prepubertal children 1, 2
- ≥5/9 points from puberty to age 50 1
- ≥4/9 points for those ≥50 years 1
The 9-point assessment includes:
- Bilateral 5th finger passive dorsiflexion >90° (2 points)
- Bilateral thumb passive apposition to forearm (2 points)
- Bilateral elbow hyperextension >10° (2 points)
- Bilateral knee hyperextension >10° (2 points)
- Forward flexion with palms flat on floor with knees straight (1 point)
Three-Criterion Diagnostic Framework
If the Beighton score is positive, apply the 2017 international consensus criteria for hEDS/HSD 1:
Criterion 1: Generalized Joint Hypermobility (above)
Criterion 2: Additional Connective Tissue Features
Look for at least 2 of the following 1:
Skin and soft tissue manifestations:
- Soft, velvety skin
- Skin hyperextensibility
- Atrophic scarring
- Unexplained striae distensae
- Piezogenic papules
- Recurrent hernias
Musculoskeletal complications:
- Chronic joint pain (>3 months, multiple joints)
- Recurrent joint dislocations/subluxations
- Joint instability
Criterion 3: Exclude Alternative Diagnoses
This is where genetic testing becomes critical. Recent evidence shows that 26.4% of patients meeting clinical hEDS criteria actually have an alternative genetic diagnosis requiring different management 3.
Order genetic testing to exclude:
- Other EDS subtypes (classical, vascular, kyphoscoliotic, etc.)
- Marfan syndrome
- Loeys-Dietz syndrome
- Other heritable connective tissue disorders
- Chromosomal abnormalities
Key caveat: Whole-exome sequencing identified alternative diagnoses in over one-quarter of clinically diagnosed hEDS patients, fundamentally changing their management 3. Do not skip genetic testing.
Assess for Associated Conditions
Once hypermobility is confirmed, targeted testing (not universal screening) should be performed only in patients with suggestive clinical manifestations 1:
POTS Evaluation (if symptomatic)
Test only if patient reports:
- Orthostatic intolerance symptoms for ≥6 months
- Palpitations, lightheadedness, tremulousness
- Cognitive dysfunction
- GI symptoms (nausea, early satiety, abdominal pain)
Diagnostic criteria:
- Heart rate increase ≥30 bpm within 10 minutes of standing (adults)
- Heart rate increase ≥40 bpm (adolescents 12-19 years) 1
- Absence of orthostatic hypotension
- Exclusion of dehydration, medications, anxiety disorders
MCAS Evaluation (if symptomatic)
Test only if patient has:
- Recurrent systemic symptoms affecting ≥2 organ systems
- Episodic anaphylaxis-like reactions
- Triggers: foods, temperature changes, mechanical stimuli, strong odors
Diagnostic requirements 1:
- Typical clinical signs of recurrent systemic mast cell activation
- Serum tryptase elevation: baseline + 20% + 2 ng/mL during episodes
- Response to histamine receptor antagonists or mast cell stabilizers
Critical point: Universal testing for POTS/MCAS in all hypermobile patients is not supported by evidence 1.
Age-Specific Considerations
For pediatric patients (<18 years):
- Use Beighton score ≥6/9 for prepubertal children 2
- Reserve hEDS diagnosis for biologically mature adolescents who meet full 2017 criteria 2
- Classify younger children into pediatric GJH or pediatric generalized HSD categories 2
- Many phenotypic features emerge over time; reassess periodically
Common Pitfalls to Avoid
Do not diagnose hEDS without genetic testing - 26.4% will have alternative diagnoses 3
Do not screen all hypermobile patients for POTS/MCAS - Only test those with clinical manifestations 1
Do not use adult Beighton cutoffs in children - This overdiagnoses hypermobility; use ≥6/9 in prepubertal children 2
Do not overlook secondary headache causes - Spontaneous intracranial hypotension, craniocervical instability, Chiari malformation, and vascular complications occur with increased frequency 4
Do not miss bleeding disorders - Assess for unexplained bleeding tendencies, as vascular fragility may cause hemorrhagic complications 5
Documentation and Referral
If positive screening but uncertain diagnosis:
- Refer to genetics for comprehensive evaluation
- Consider rheumatology for musculoskeletal management
- Cardiology/neurology consultation if POTS suspected
- Gastroenterology if significant GI symptoms present
The workup is algorithmic: Beighton score → Apply 2017 criteria → Genetic testing to exclude alternatives → Targeted evaluation for POTS/MCAS only if symptomatic.